As previously described, one of the promising human TNBC therapies is the inhibition of the PI3K/AKT/mTOR pathways, particularly mTOR, which is more frequently expressed in TN cancer compared with its non-TN counterparts[3] and is considered to be a potential anticancer therapy molecular target[9,13-15]. The gene discussed is AKT1; the disease is cancer.